Menu
Not yet recruiting NCT07150520

VR-Based Optokinetic Stimulation in Multiple Sclerosis

No phase Interventional Multiple Sclerosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Virtual Reality-Based Optokinetic Stimulation (OKS).
Who it may be relevant to
Registry conditions: Multiple Sclerosis. Basic parameters: 18 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Acute Effects of Virtual Reality-Based Optokinetic Stimulation in Individuals With Multiple Sclerosis: Does Central Vestibular Dysfunction Alter These Effects?

Overview

The aim of this study is to investigate the acute effects of virtual reality-based optokinetic stimulation on postural sway and motion sickness symptoms in individuals with multiple sclerosis (MS)

Detailed description

This study will be conducted at Hacettepe University, Faculty of Physical Therapy and Rehabilitation. It will investigate the acute effects of virtual reality-based optokinetic stimulation (OKS) on postural sway and motion sickness symptoms in individuals with multiple sclerosis (MS). Participants will include MS patients with and without central vestibular dysfunction, as well as age- and sex-matched healthy controls. MS participants will first undergo vestibular function assessment using videonystagmography (VNG). Postural control will then be measured via a force platform under four conditions (bipodal/monopodal, eyes open/closed) before and after a 10-minute OKS session using Oculus Quest 2. Healthy participants will follow the same postural and OKS assessment protocol without VNG.Motion sickness and virtual reality effects will be evaluated using the Simulator Sickness Questionnaire. Data will be analyzed using appropriate parametric or non-parametric tests to compare postural sway and VR-related symptoms across groups, with significance set at p \< 0.05.

Interventions

  • Device Virtual Reality-Based Optokinetic Stimulation (OKS)
    A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.

Primary outcome measures

  • Postural Sway [Time frame: Immediately before and immediately after the 10-minute virtual reality-based optokinetic stimulation session]

Eligibility criteria

Inclusion criteria

  • Be an adult aged 18-55 years
  • Have a confirmed diagnosis of MS by a neurologist (for MS groups)
  • Not have had a relapse in the last 3 months (for MS patients)
  • Have an Expanded Disability Status Scale (EDSS) score of ≤ 4 (for MS patients)
  • Be a healthy control with no condition preventing participation

Exclusion criteria

  • Have peripheral vestibular dysfunction (for MS groups)
  • Be older than 55 years
  • Have any cardiovascular, orthopedic, neurological, or other condition preventing assessments
  • Have a history of neurological disorders, head trauma, or chronic psychiatric conditions (for healthy controls)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07150520 · 2025/102

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗